Xue Bai

Title: Innovations of Xue Bai in Monoclonal Antibody Development

Introduction

Xue Bai is a notable inventor based in Changchun, China. He has made significant contributions to the field of biotechnology, particularly in the development of hybridoma cell strains and monoclonal antibodies. His work focuses on the prevention and treatment of infectious diseases, showcasing his commitment to advancing medical science.

Latest Patents

Xue Bai holds a patent for a "Hybridoma cell strain and monoclonal antibody produced therefrom against serine protease of intestinal stage and application thereof." This invention addresses the technical problem of specifically diagnosing trichinellosis. The patent discloses a hybridoma cell strain deposited under the accession number CGMCC No. 18317. The monoclonal antibody Ts-ZH68-2A4-Ab secreted by this hybridoma cell strain has shown the ability to compete with the positive serum of pigs infected with the disease for binding to the Ts-ZH68 antigen. The recognition peptide identified in this process is GVDRSATCQGDSGGP. This innovation lays the groundwork for developing a serological diagnosis method for trichinellosis.

Career Highlights

Xue Bai is affiliated with Jilin University, where he continues to engage in research and development in the field of immunology. His work has not only contributed to scientific knowledge but also has practical applications in diagnosing and preventing infections.

Collaborations

Xue Bai has collaborated with colleagues such as Mingyuan Liu and Xiaolei Liu, enhancing the research output and fostering a collaborative environment in their scientific endeavors.

Conclusion

Xue Bai's innovative work in developing monoclonal antibodies represents a significant advancement in the field of medical diagnostics. His contributions are vital for the ongoing fight against infectious diseases, particularly trichinellosis.